Stefan Kaufmann

Director/Board Member at Bio Ventures for Global Health

76 year

Consumer Services

Health Technology

Profile

Stefan Kaufmann is currently the Director at Bio Ventures for Global Health.
He is also a Member-Supervisory Board at Vakzine Projekt Management GmbH since 2012.
Previously, he worked at PricewaterhouseCoopers LLP.
Dr. Kaufmann was a Professor at Universität Ulm from 1987 to 1998.
He holds a doctorate degree from The Johannes Gutenberg University of Mainz and an undergraduate degree from Max-Planck-Institute for Molecular Genetics.

Stefan Kaufmann active positions

Companies	Position	Start
Vakzine Projekt Management GmbH Vakzine Projekt Management GmbH Pharmaceuticals: MajorHealth Technology Vakzine Projekt Management GmbH develops vaccines and biopharmaceuticals products from laboratory stages through to clinical examination. It offers VPM2001 vaccine to prevent human cytomegalovirus infections and VPM5001 Soluferon vaccine, treatment for multiple sclerosis (MS) and hepatitis C. The company was founded in August 2002 and is headquartered in Hannover, Germany.	Corporate Officer/Principal	-
Bio Ventures for Global Health	Director/Board Member	-

All active positions of Stefan Kaufmann

Former positions of Stefan Kaufmann

Companies	Position	End
Universität Ulm	Corporate Officer/Principal	1997-12-31

See the detail of Stefan Kaufmann's experience

Training of Stefan Kaufmann

Max-Planck-Institute for Molecular Genetics	Undergraduate Degree
The Johannes Gutenberg University of Mainz	Doctorate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Stefan Kaufmann's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	2
Vakzine Projekt Management GmbH Vakzine Projekt Management GmbH Pharmaceuticals: MajorHealth Technology Vakzine Projekt Management GmbH develops vaccines and biopharmaceuticals products from laboratory stages through to clinical examination. It offers VPM2001 vaccine to prevent human cytomegalovirus infections and VPM5001 Soluferon vaccine, treatment for multiple sclerosis (MS) and hepatitis C. The company was founded in August 2002 and is headquartered in Hannover, Germany.	Health Technology
Bio Ventures for Global Health